{"slideshow_credits": null, "snippet": "A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety.", "abstract": "Federal advisory panel recommends approval of Pfizer's rheumatoid arthritis pill tofacitinib, but several members express concern about its safety and urge the Food and Drug Administration to require rigorous follow-up studies.", "section_name": "Health", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2012/05/10/health/panel-supports-arthritis-pill.html", "lead_paragraph": "A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety.", "headline": {"seo": "Pfizer&#8217;s Rheumatoid Arthritis Pill Wins Federal Panel&#8217;s Approval", "main": "Arthritis Pill From Pfizer Wins Support of U.S. Panel", "print_headline": "Arthritis Pill From Pfizer Wins Support Of U.S. Panel"}, "_id": "53f6937638f0d821a37b2398", "word_count": "422", "multimedia": [], "pub_date": "2012-05-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Rheumatoid Arthritis", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Accidents and Safety", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "4"}, {"value": "Pfizer Inc", "name": "organizations", "is_major": "Y", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}